Investorideas podcasts on iTunes, Google Play Music and potcasts - cannabis news and stocks to watch plus insight from thought leaders and experts crypto corner    Play by Play – the latest sports headlines and sports stock news    420 Cannabis Investor Ideas Call us 800 665 0411


Join our smart investors - Get the best stock directories in  blockchain, cannabis, crypto, AI, IoT, cleantech. Daily podcasts in cannabis and crpto. Just $99  a year

Digital Therapeutics Adoption to Soar, Treating 130 Million Sufferers of Chronic Conditions by 2023

Use of app-based treatments to increase to 27 times current levels by 2023


Hampshire, UK - April 24, 2018 ( Newswire) A new study from Juniper Research found that digital therapeutics software, clinically proven to treat medical conditions, will be adopted enthusiastically by many healthcare stakeholders. The number of people using digital therapeutics will increase from an estimated 4.5 million in 2018 to 130 million by 2023.

For more insights on digital therapeutics, download our complimentary whitepaper: Top 3 Medical Conditions to Benefit from Digital Therapeutics, is available to download from the Juniper Research website together with details of the new research and interactive dataset.

Businesses Buy into Healthcare Savings

The new research, Digital Therapeutics & Wellness: Disruption, Innovation Opportunities & Forecasts 2018-2023, found that growth will be fuelled by self-insuring businesses in the US wanting to save on costs, as well as interest from healthcare providers and insurers.

Compared to medical bills for chronic conditions, digital therapeutics subscriptions, costing a few hundred dollars per person per year, offer large savings on drug costs and their inherent potential complications. Juniper anticipates revenue from self-insured employer-paid digital therapeutics will exceed $5.2 billion in 2023.

New Opportunities for Pharma & Health Insurance

The research found significant opportunities for businesses that manage healthcare systems and integration, as well as for health insurers. Insurers could also potentially offer digital therapeutics for some conditions without reference to drug companies. Juniper expects annual spend from insurers to reach $6.3 billion by 2023. However, this is dependent on being able to integrate digital therapeutics into existing healthcare workflows.

Investment by drug companies in this area has been limited so far. Juniper considers digital therapeutics to be both an opportunity and threat for pharmaceutical companies, as it could offer new business for them, but also erode their revenues through insurers developing or acquiring their own treatment platforms.

"Our research shows that the average time from development to commercialisation for a digital therapeutic is 3-4 years," notes research author James Moar. "This gives drug companies and insurers an opportunity to bring chronic condition treatment to market in a fraction of the time and cost of drug development."

Juniper Research provides research and analytical services to the global hi-tech communications sector, providing consultancy, analyst reports and industry commentary.

Contact: - investing ideas in tech stocks - mobile payments, social media, AI and Robotics, Drone Stocks, GPS, Internet of Things (IoT)

Like Tech Stocks? View our Tech Stocks Directory  Get News Alerts on Tech Stocks

More Info: Newswire

This news is published on the Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: Learn more about publishing your news release on the newswire

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: Global investors must adhere to regulations of each country.

Please read privacy policy: